Two of a kind: mass and molar immunoassay-based lipoprotein (a) concentrations are similarly prognostic for MACE risk and predictive of alirocumab benefit in ODYSSEY OUTCOMES

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Biomarkers for risk stratification in acute coronary syndromes (2) Biomarkers ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

ESC 365 is supported by

ESC 365 is supported by